)
Shares of Claris Lifesciences is locked in upper circuit of 20% at Rs 248, also its 52-week high on BSE, on reports that big pharmaceutical companies eyes the company’s injectables business for about Rs 3000 crore.
The Exchange said it has sought clarification from Claris Lifesciences with respect to news printed in The Economic Times on February 12, 2015 titled "Big Pharma Eyes Claris' Injectables Biz for Rs 3kcr". The reply is awaited.
“Several Indian pharma giants are competing with their global peers as the race to acquire the generic sterile injectables business of Ahmedabad-headquartered Claris Lifesciences,” the Economic Times report suggests.
Till 1216 hours, around 744,000 shares changed hands against an average 144,000 shares that were traded daily in past two weeks. There are pending buy orders for 271,774 shares on BSE.
The Exchange said it has sought clarification from Claris Lifesciences with respect to news printed in The Economic Times on February 12, 2015 titled "Big Pharma Eyes Claris' Injectables Biz for Rs 3kcr". The reply is awaited.
“Several Indian pharma giants are competing with their global peers as the race to acquire the generic sterile injectables business of Ahmedabad-headquartered Claris Lifesciences,” the Economic Times report suggests.
Till 1216 hours, around 744,000 shares changed hands against an average 144,000 shares that were traded daily in past two weeks. There are pending buy orders for 271,774 shares on BSE.
